Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 1
1988 1
1989 2
1995 2
1996 1
1997 1
1998 1
1999 1
2005 1
2006 1
2007 3
2008 3
2009 1
2010 1
2011 2
2013 1
2014 1
2015 1
2016 1
2017 1
2018 3
2019 2
2020 7
2021 4
2022 7
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

49 results

Results by year

Filters applied: . Clear all
Page 1
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Among authors: torrea g. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.
Multidrug-resistant tuberculosis control in Rwanda overcomes a successful clone that causes most disease over a quarter century.
Ngabonziza JCS, Rigouts L, Torrea G, Decroo T, Kamanzi E, Lempens P, Rucogoza A, Habimana YM, Laenen L, Niyigena BE, Uwizeye C, Ushizimpumu B, Mulders W, Ivan E, Tzfadia O, Muvunyi CM, Migambi P, Andre E, Mazarati JB, Affolabi D, Umubyeyi AN, Nsanzimana S, Portaels F, Gasana M, de Jong BC, Meehan CJ. Ngabonziza JCS, et al. Among authors: torrea g. J Clin Tuberc Other Mycobact Dis. 2022 Jan 24;27:100299. doi: 10.1016/j.jctube.2022.100299. eCollection 2022 May. J Clin Tuberc Other Mycobact Dis. 2022. PMID: 35146133 Free PMC article. Review.
A Trial of a Shorter Regimen for Rifampin-Resistant Tuberculosis.
Nunn AJ, Phillips PPJ, Meredith SK, Chiang CY, Conradie F, Dalai D, van Deun A, Dat PT, Lan N, Master I, Mebrahtu T, Meressa D, Moodliar R, Ngubane N, Sanders K, Squire SB, Torrea G, Tsogt B, Rusen ID; STREAM Study Collaborators. Nunn AJ, et al. Among authors: torrea g. N Engl J Med. 2019 Mar 28;380(13):1201-1213. doi: 10.1056/NEJMoa1811867. Epub 2019 Mar 13. N Engl J Med. 2019. PMID: 30865791 Free article. Clinical Trial.
Failure or relapse predictors for the STREAM Stage 1 short regimen for RR-TB.
Kokebu DM, Ahmed S, Moodliar R, Chiang CY, Torrea G, Van Deun A, Goodall RL, Rusen ID, Meredith SK, Nunn AJ. Kokebu DM, et al. Among authors: torrea g. Int J Tuberc Lung Dis. 2022 Aug 1;26(8):753-759. doi: 10.5588/ijtld.22.0073. Int J Tuberc Lung Dis. 2022. PMID: 35898125 Free PMC article.
Management of falsepositive rifampicin resistant Xpert MTB/RIF - Authors' reply.
Ngabonziza JCS, Decroo T, Torrea G, Migambi P, Van Deun A, Rigouts L, de Jong BC. Ngabonziza JCS, et al. Among authors: torrea g. Lancet Microbe. 2020 Oct;1(6):e239. doi: 10.1016/S2666-5247(20)30125-7. Epub 2020 Oct 7. Lancet Microbe. 2020. PMID: 35544219 Free article. No abstract available.
49 results